NCT04878484: Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: HLA+, ESO
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that are HLA-A*0201 positive & NY-ESO-1 positive
Exclusions: Patients with untreated or symptomatic brain metastasis

Comments are closed.

Up ↑